Abstract Hyperlipidemic myeloma is a rare and poorly understood variant of multiple myeloma. We report the case of a 53-year-old woman with hyperlipidemic myeloma, skin xanthomas and hyperviscosity syndrome who underwent allogeneic bone marrow transplantation. A comprehensive literature search identified 52 additional cases with plasma cell disease and hyperlipidemia. A detailed analysis revealed several characteristics of these patients as compared to multiple myeloma with normal lipid status: (1) IgA paraprotein was present in the majority (53% vs. 21% in classical multiple myeloma). (2) Skin xanthomas, especially in the palmar creases, elbows, and knees were common (70%). (3) Hyperviscosity syndrome occurred more often (26% vs. 2-6%). While conventional lipid-lowering therapy had only marginal effects, successful anti-myeloma therapy also reduced hyperlipidemia. Analyses of the mechanisms leading to hyperlipidemia documented complexes of paraprotein and lipoprotein in 75% of the 32 cases tested, suggesting an inhibitory role of the paraprotein on lipid degradation. In conclusion, the clinical characteristics, the therapeutic options, and the pathophysiologic mechanisms of hyperlipidemic myeloma are comprehensively reported using the available data from all 53 published cases in the literature.
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Introduction
Hyperlipidemic myeloma (HLM) is a rare variant of multiple myeloma [4] . While it may present as an isolated laboratory finding, in some cases it is associated with skin xanthomas and/or hyperviscosity syndrome, dominating the clinical picture. Since previous comprehensive reports of HLM date back 30 years [4, 11, 43, 52, 63] and due to its low incidence, symptoms, the clinical course, and the best therapy of HLM remain largely unknown. Even though the unusual lipid patterns, occasionally manifesting as a grossly lipemic and highly viscous serum were studied extensively in some cases, the underlying mechanism of HLM remains unknown. According to one hypothesis, the paraprotein binds to lipoproteins and, thereby, inhibits their degradation [2, 4, 6, 13, 37, 63] . This view has been challenged, and evidence for an affinity of the paraprotein to heparin or the low-density lipoprotein (LDL) receptor was provided, leaving the matter open for debate [12, 13, 52, 66] . Here, we present a patient with HLM who was treated with allogeneic bone marrow transplantation, as well as an extensive literature research revealing a total of 52 additional cases.
Case presentation
In 2003, a 53-year-old woman with HLM was referred for allogeneic hematopoietic stem cell transplantation; the time course of events is shown in Fig. 1 
Patients and methods
A PubMed search was carried out using the search terms "hyperlipidemia", "hypertriglyceridemia" or "hypercholesterolemia", "multiple myeloma", and "paraproteinemia" or "paraprotein". Case reports published until June 2007 written in English, French, Spanish, German, Russian, and Czech fulfilling both of the following criteria were included: (1) paraproteinemia or an abnormal plasma cell clone in bone marrow or tissue biopsy; (2) hypertriglyceridemia >5 mmol/ l or hypercholesterolemia >8.5 mmol/l. These high threshold values were chosen arbitrarily to exclude dyslipidemia of metabolic syndrome. Plasma cell disease was classified following international guidelines [29, 47] as monoclonal gammopathy of unknown significance (MGUS), multiple myeloma, or smoldering multiple myeloma. Since many reports lacked complete documentation of end organ damage, a plasma cell count of >30%, extensive bone marrow infiltration or pronounced atypia were also considered diagnostic for multiple myeloma. Complete remission (CR) for myeloma was defined as lack of any evidence of myeloma after treatment; partial remission (PR) required marked decrease of the paraprotein level. Similarly, CR required a normalization, and PR a marked improvement of lipid levels. Statistical analysis was carried out using Graphpad Prism® and included linear regression, Fisher's exact test, MannWhitney testing, and a survival analysis tool. Due to the fact that this meta-analysis contains incomplete data sets, p values have to be interpreted with caution.
Results
Baseline characteristics and laboratory values A total of 52 additional cases of HLM published between 1937 and 2007 were identified ( Table 1 ). The majority (85%) fulfilled the criteria of multiple myeloma; in addition, four cases (7.5%) were classified as smoldering myeloma and four cases as MGUS (Table 2) . Overall, these patients differed from a large published myeloma cohort [35] by a predominance of IgA myeloma (53.3% vs 21%), while IgG (42% vs. 51.5%) light chain and nonsecreting myeloma (0% vs 3% and 20%, respectively) were underrepresented. In contrast, the distribution of kappa-and lambda myeloma was identical. HLM patients were slightly younger at diagnosis (57 years, range 21-74 vs 66 years old, range 20-92), and a slight male preponderance (30 cases vs. 23) was noted. The median triglyceride value was 11.5 mmol/l (range 2.4-65.7) and the median cholesterol level 16.5 mmol/ l (3.5-49.2). Cholesterol levels of patients with IgA myeloma were higher than with IgG myeloma (Fig. S1) . A striking correlation between paraprotein and lipid concentrations was observed in our patient (R 2 =0.84 and 0.74 for cholesterol and triglycerides, respectively, Fig. S2 ), in line with similar longitudinal data reported for 12 additional patients. Additional conditions aggravating hyperlipidemia were present in seven patients including nephrotic syndrome (four), diabetes mellitus (two), and hypothyroidism (one). The serum was reported to be milky, turbid, oily, or lipemic in 24 cases, sometimes with a creamy cap.
Clinical presentation Typically, symptoms of hyperlipidemia or xanthomas preceded the diagnosis of plasma cell disease in 21 and 22 cases, respectively, sometimes by more than 10 years (mean delay 4.1 and 3.6 years, respectively, Table S1 ). In other patients, plasma cell disease was diagnosed simultaneously (23 and four cases) or even before (five and three cases) the hyperlipidemic and xanthoma symptoms. Skin xanthomas were described in 37 of 53 patients (70%), typically, the palmar creases of the hands were involved, but the periorbital region, elbows, and knees were also concerned (Table S2 ). In general, xanthomas were painless; however, for five patients, painful lesions dominated Immunoglobulin deposition was detected in one skin biopsy and one surgical sample of an artery, four skin biopsies tested negative for immunoglobulins. Hyperviscosity syndrome occurs in 2-6% of myeloma patients [41] , but developed in 14 HLM patients (26%) causing symptoms of bleeding in five patients including two with retinal hemorrhage, ischemia of the lower limbs (two) or abdominal organs (three). Mental changes were noted in eight patients including symptoms of confusion, headache, dizziness, ataxia, nausea, and prolonged unconsciousness. In 14 patients, plasmapheresis was performed, 11 for documented hyperviscosity, and an additional three for unclear reasons. Atherosclerosis was common among HLM patients (Table S3 ) affecting more than a fourth of all patients (15 out of 50 cases with sufficient data). Typically, the coronary arteries were involved (ten patients) followed by lower limbs (four cases) and cerebral arteries (two cases). In contrast to a predominance of atherosclerosis among cases published before 1975 (14 out of 25 patients), it was much less often observed within the last 30 years (four out of 25).
Treatment Anti-myeloma chemotherapy was applied in 33 patients (Table S4) , two of which (including the present case) were treated by autologous and allogeneic bone marrow transplantation. In 14 patients, a partial or complete response, typically for a limited time period was documented. In all of these patients, the lipid levels markedly improved or even normalized. Anti-myeloma treatment of six patients with skin xanthomas induced complete normalization and marked improvement of skin symptoms in two patients, respectively. Pharmacological treatment of hyperlipidemia was reported in 19 patients (Table S5 ). Most commonly, fibrates were used (total 13 cases, 11 with sufficient data) resulting in lipid normalization in one and an improvement in seven patients. Other drugs also resulted at best in a partial response (two out of five for statins, three out of five for niacine, two out of six for cholestyramin/cholestipol, and three out of four for probucol).
Outcome Both, progression of myeloma and atypical hyperlipidemia determined the outcome of the disease. Twenty-five patients died, 11 of them because of myeloma complications including infections (seven), renal failure (three), and progression of myeloma (one). The causes of death for 12 of the remaining patients were myocardial infarction (five), sudden cardiac death (one), heart failure (three), hyperviscosity syndrome (two), and pancreatitis (one). A Kaplan-Meier estimation of median overall survival of multiple myeloma patients with HLM (28 months) was slightly shorter than in patients with normal multiple myeloma (30 months). Median survival of patients with smoldering myeloma or MGUS tended to be longer.
Pathophysiology
The mechanisms leading to hyperlipidemia in patients with HLM are not known. In general, hyperlipidemia might either be due to an increased lipid synthesis or decreased lipid degradation. The half-life of lipids was tested experimentally in six cases, four times in vivo using labeled lipids, and twice in tissue culture. Uniformly, a prolonged half-life for lipids was demonstrated suggesting decreased lipid degradation as the mechanism causing hyperlipidemia. Physical binding of paraprotein and lipoprotein was demonstrated in 24 of 32 cases tested (Table 3) . Co-migration in electrophoresis (14/19) and ultracentrifugation (12/18) were frequently employed to demonstrate complex formation. Binding activity was found to be within the Fab fragment of the antibody in all four cases tested. In five cases, the paraprotein was purified and a complex of lipoproteins and paraprotein was reconstituted with normal serum, suggesting that properties of the paraprotein and not the lipoprotein were responsible for the formation of this abnormal complex. In contrast, in 12 of the 28 patients tested, evidence against complex formation was found in at least one assay (Table 3) . Sometimes, different assays yielded contradictory results within a single patient. Moreover, in a minority of patients, no association of paraprotein and lipoprotein could be documented at all and different pathophysiological mechanisms were suggested: In some cases, lipolytic activity in the serum after injection of heparin was found to be low (Table 3 ). In two patients, the paraprotein had an affinity to heparin, which is an essential co-factor for lipases. In another case, blocking of the LDL receptor by the paraprotein inhibited lipid degradation.
Discussion
Summarizing the available data for all reported cases of HLM, the typical clinical presentation is characterized by IgA myeloma, hyperlipidemia, and skin xanthomas of palmar creases, hands and knees, and hyperviscosity which may dominate the clinical picture. HLM can be associated with artherosclerosis; however, since it was less frequently diagnosed in recent years, we believe that overall better treatment and prophylaxis may delay the onset of atherosclerosis. The best therapy for HLM has not been defined; in most patients, pharmacological lipid-lowering therapy was largely ineffective. In contrast, even partially successful anti-myeloma chemotherapy resulted in clear improvement of the lipid levels. In some cases, lipid values were conveniently used as disease marker for HLM. The effect of anti-myeloma chemotherapy on xanthomas was less impressive. Most likely, reversing xanthomas requires a prolonged period with normal or near normal lipid and paraprotein levels which was not achieved in most patients. HLM is considered to be an exceedingly rare clinical entity. Indeed, in a large study, only 6% of 300 myeloma patients tested had cholesterol levels above 7.76 mmol/ l including 1% above 12.9 mmol/l [34] . In the same study, 2% of 131 patients tested had triglyceride levels >3.4 mmol/l, all of these values were elevated above 5.7 mmol/l. However, the most common lipid abnormality of multiple myeloma seems to be a low cholesterol level: in 26% of the 300 patients the cholesterol levels were below 3.9 mmol/l; and 13% had cholesterol levels below 0.57 mmol/l [34] . Nevertheless, since lipid levels were only reported in a subgroup of myeloma patients, lipid abnormalities might be an underdiagnosed condition.
The mechanisms leading to hyperlipidemia are not entirely clarified. In two-thirds of the patients tested, a complex between paraprotein and lipoprotein was demonstrated. In these cases, the antibody seems to cover the lipoprotein, preventing steric access of lipases and reducing lipid degradation. The epitopes recognized by the antibody are largely unknown; in some cases, the paraprotein was able to bind lipoproteins derived from a wide range of species (fish to mammals, HDLs to VLDLs), suggesting unspecific binding to universal components of lipoproteins. For other paraproteins, the substrate range was more specific. The affinity of the paraprotein to its lipoprotein target is most likely week: in most cases, hyperlipidemia occurred while the paraprotein concentration was high and resolution required lowering, but not disappearance of the paraprotein. For unknown reasons, the pathological process leading to hyperlipidemia seems to be better supported by IgA than by IgG molecules. In a minority of patients, complexes between paraprotein and lipoproteins were not detected despite considerable experimental efforts. On the one hand, a week or transient interaction might have evaded detection, on the other hand, a different mechanism might be responsible for hyperlipidemia in these patients. An inhibition of lipoprotein lipases, possibly via an affinity towards the co-factor heparin was proposed, as well as blocking of the cellular LDL receptor.
Complexes of lipoprotein and paraprotein might be more common than appreciated. In some of the myeloma patients with hypocholesterolemia, an affinity of paraprotein towards lipoprotein was also demonstrated [38, 51, 57, 61] . It has been speculated that the paraprotein opsonises the lipoprotein followed by degradation by macrophages [50] . In one of these studies, the serum of 20 patients with detectable affinity of paraproteins to lipoproteins had significantly lower total lipid values then the sera of 38 patients without this activity [51] . It remains mysterious as to what features of the antibody are increasing or decreasing the degradation of the lipoproteins in hyperlipidemic versus hypolipidemic myeloma.
In many aspects, patients with HLM mimic the disease familial dysbetalipoproteinemia (FD). Patients suffering from this condition also have elevated cholesterol and triglyceride levels and develop similar skin xanthomas [59] . Lipid electrophoresis demonstrates a typical broad beta peak in FD patients. Even though documentation was incomplete, at least 15 reported patients with HLM revealed a similar electrophoretic pattern. However, FD is not known to be associated with multiple myeloma and responds promptly to lipid-lowering therapy. The genotype E2/E2 or rare mutations of the apolipoprotein E (ApoE) gene are responsible for FD. ApoE is present on LDLs and serves as a co-receptor for the LDL receptor. The affinity of the ApoE2 allele to its receptor is 100-fold weaker, causing a reduced uptake of LDL and, consequently, accumulation of lipoproteins. However, only a fraction of patients with this genotype develops hyperlipidemia, typically in association with other diseases such as diabetes mellitus or hypothyroidism. The ApoE genotype was tested in nine patients with HLM, two were homozygous for E2, and five heterozygous. In contrast, the frequencies for the E2/E2 and E2/E3 genotypes in the normal population are 1% and 10%, respectively. It is tempting to speculate that covering of the lipoproteins with antibodies in the setting of a partially or completely deficient LDL co-receptor causes hyperlipidemia. However, in the two patients (including ours) that were of the E3/E3 genotype, other so far unrecognized pathogenetic mechanisms must be responsible for hyperlipidemia.
In summary, the association of multiple myeloma and hyperlipidemia is a rare but clinically relevant and scientifically fascinating condition. Since many features of the disease remain unresolved, further work with systematic biochemical experiments in a larger series of patients is needed. These biochemical data in combination with clinical and genetic data might clarify the mechanism of this association.
